Kenvue Inc. (KVUE) reports developments as a pure-play consumer health company with a brand portfolio that includes Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its updates center on consumer health categories, operating and financial results, and board actions such as cash dividends on common stock.
Recurring news themes also include material agreements, capital-structure matters, governance changes, shareholder voting topics and consumer-health regulatory disclosures. The coverage reflects Kenvue’s role as a public company operating branded everyday-care products across personal care, oral care, pain management and related health categories.
Kimberly-Clark (KMB) announced planned executive transitions and revised leadership assignments for the combined company following its pending acquisition of Kenvue.
President and Chief Operating Officer Russ Torres, who also heads integration management, will leave for an external CEO role and remain until November. Kenvue's Carlos De Jesus will lead North America after closing; Kimberly-Clark's John Carmichael will leave shortly afterward. Kenvue's Leonardo Curado will lead Europe, Middle East and Africa effective January 1, 2027, while Carlton Lawson will step down at year-end. Kimberly-Clark expects the acquisition to close in the fourth quarter of 2026, subject to regulatory approvals and other remaining customary closing conditions.
Kenvue (KVUE) is launching LISTERINE’s multiyear Oral Care Counts education and advocacy initiative for World Smile Day on October 2, 2026.
The campaign aims to improve understanding of oral health and encourage daily brushing, flossing and, where appropriate, mouthrinse use. It will operate in the United States and other markets globally, focusing on prevention, affordability and access. Planned activities include professional education and preventive-care resources through organizations including the American Dental Hygienists Association, Meijer and the National Community Pharmacists Association.
Kenvue (KVUE) will present 12 scientific data sets from Neutrogena, Aveeno and Regaine at the EADV dermatology congress in Vienna. The congress runs September 30–October 3, 2026.
In two small Brazilian populations, a Neutrogena sunscreen study reported a 56% reduction in visible redness after 28 days and a 46% reduction in acne-related hyperpigmentation. Another sunscreen study reported 22% improved hydration in women with dry skin. Aveeno preclinical and clinical research found improved skin-barrier recovery with oat-containing formulations.
A post-hoc analysis, conducted after a Phase III trial, found greater hair regrowth with Regaine 5% minoxidil foam among younger men and those with earlier-stage hair loss. After 16 weeks, average hair-count increases were 26.25 in men aged 20–30 versus 19.93 in men older than 30. Improvements versus placebo were statistically significant across all hair-loss classifications studied.
Kimberly-Clark (KMB) launched an exchange offer for Kenvue (KVUE) notes, proposing up to $7 billion in new notes and cash.
For each $1,000 of Kenvue notes accepted, eligible holders tendering by October 9, 2026, can receive $1,000 in Kimberly-Clark notes and $1 in cash. Later tenders receive $970 in notes, without the early premium or cash. The offers expire October 27, 2026, unless extended or terminated. The replacement notes retain the corresponding series’ interest rates, payment dates, maturities and optional redemption prices.
Kimberly-Clark is also seeking consent to remove most restrictive covenants and certain default and reporting provisions from Kenvue’s note indenture. Approval requires a majority of the outstanding principal in each series voting separately. Approved changes would also govern notes left outstanding in that series. The exchange depends on completion of the pending Kenvue acquisition, expected in the fourth quarter of 2026.
Kenvue (KVUE) declared a quarterly cash dividend of $0.21 per share on its common stock. The dividend will be paid on October 2, 2026 to shareholders of record as of the close of business on September 21, 2026.
Kenvue describes itself as the world’s largest pure-play consumer health company by revenue, with brands including Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena and Tylenol.
Kimberly-Clark (NASDAQ: KMB) has appointed Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Chief Strategy, Business Development and Administrative Officer Jeff Melucci and join Kimberly-Clark's Executive Leadership Team.
Blades is also named to the leadership team that will take effect upon completion of Kimberly-Clark's pending acquisition of Kenvue (NYSE: KVUE). She previously served as Vice President & Deputy General Counsel overseeing global litigation, government relations, legal operations and the Natural Solutions business, and earlier held senior legal roles at ConocoPhillips, Hess and Arnold & Porter.
Kenvue (NYSE: KVUE) reported fiscal Q2 2026 results for the quarter ended June 28, 2026, with Net sales up 3.0%, driven by 1.6% Organic sales growth and a 1.4% foreign currency benefit. Diluted EPS rose 9% to $0.24, while Adjusted diluted EPS increased 7% to $0.31. Gross profit margin was 58.2% (Adjusted 60.2%), and Operating income margin was 17.7% (Adjusted 22.1%), both modestly lower year over year.
All three segments – Self Care, Skin Health and Beauty, and Essential Health – delivered Net sales growth between 2.2% and 5.1%. For the first six months, operating cash flow reached $1.2 billion, with Free cash flow of $1.0 billion. The company highlighted FDA approval of Tylenol with Naproxen, a new OTC fixed-dose combination granted three-year exclusivity. Kenvue also referenced its pending cash-and-stock acquisition by Kimberly-Clark, expected to close in Q4 2026 subject to remaining foreign regulatory approvals and customary conditions, and a 2026 Restructuring Initiative targeting about $250 million in pre-tax charges to optimize operations.
Kenvue (NYSE: KVUE) announced that its Board of Directors has declared a quarterly cash dividend of $0.21 per share on its common stock, a 1.2% increase from the prior quarterly dividend. The dividend will be paid on August 26, 2026 to shareholders of record as of August 12, 2026.
Kenvue (NYSE: KVUE) plans to release its second quarter 2026 financial results before the market opens on August 6, 2026. Due to its pending transaction with Kimberly-Clark, Kenvue will not hold a quarterly earnings conference call. The earnings press release will be available at investors.kenvue.com.
Kenvue (NYSE: KVUE) reported Q1 2026 results: net sales +4.5%, organic sales +0.7%, diluted EPS $0.25 (+47%), adjusted diluted EPS $0.32 (+33%). Gross margin expanded to 58.9% and adjusted gross margin to 60.8%. Operating margin widened to 19.6% and adjusted operating margin to 24.0%. Free cash flow rose to $0.4 billion. The company reaffirmed the expected close of its Kimberly-Clark transaction in H2 2026, subject to regulatory approvals, and disclosed a 2026 restructuring charge of about $250 million.